Finally, in individuals with PML, a significant number of patients receiving anti-PD-1 had fewer cerebrospinal fluid JCPyV genome copies, elevated JCPyV-specific CD4 and CD8 T cell responses, and importantly, clinical improvement or disease stabilization (96, 97). The gene discussed is CD8A; the disease is progressive multifocal leukoencephalopathy.